Tagged with Artificial Intelligence

Opinion Professor Jackie Hunter looks at why the pharmaceutical industry has been so slow to adopt artificial intelligence-based technologies and makes a prediction for the industry’s future, including a significantly increased amount of interplay between large technology and pharma companies.   The past two decades have seen an explosion of biomedical…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in mergers and acquisition (M&A) activities involving companies with artificial intelligence/machine learning platforms and technologies and their application to healthcare companies.   Artificial Intelligence Advances in technologies, an incorporation of entrants from outside the industry and changing consumer…

Opinion Vishal Doshi looks at how AI is already revolutionising healthcare in Asia-Pacific and the work still to be done on the foundational elements – infrastructure, regulations, and the availability of Asia-specific data – to ensure AI can be effectively utilised to improve patient outcomes in the region.   Healthcare, manufacturing,…

France With Minister of the Economy and Finance, Bruno Le Maire, emphasizing the importance of “winning the battle on data” and eccentric mathematician Cédric Villani, well in the process of drawing up a national strategy on artificial intelligence (AI) in his capacity as Chargé de Mission, there is little doubting the…

Opinion Dr Kamala Maddali looks at how artificial intelligence is currently being utilized across the healthcare spectrum and why the time is now for Big Pharma to adopt this technology more fully.   The beauty of artificial intelligence is that it allows one to assess both forest and tree.   A…

China Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its partnership strategy, and the complexities of attracting and retaining talent in the highly competitive Chinese market.   In 2014, my first angel investor actually…

Opinion Krishna Cheriath, chief data officer at BMS, outlines the ways in which AI is already transforming the delivery of healthcare, what modern biopharma companies’ AI innovation agendas should include, and why behavioural change is a key tenet in securing meaningful health outcomes with AI.   As Biopharma increases AI investments,…

Opinion Bayer’s Michael Levy examines how artificial intelligence (AI) can assist in both the routine and advanced analytical tasks involved in conducting pharmacovigilance and therefore better ensure the safety of pharmaceuticals and the health of patients.   Pharmacovigilance or Patient Safety aims to promote and protect the health and well-being of…

Opinion Pierre Meulien of the Innovative Medicines Initiative (IMI) discusses the potential impact that new technological innovations will have on the drug development process.   A more technologically integrated approach is required that looks more holistically at the patient as an individual Whether we call it “Personalised”, “Precision”, “Stratified”, or “Tailored”, the age…

AI Axel Schumacher highlights the vital importance of AI and blockchain for the future success of pharmaceutical companies, the significant knowledge gap that currently exists within Big Pharma, and why, therefore, now is the time for these firms to invest in AI and blockchain start-ups.   While almost everyone is talking…

AI Digital marketing expert Buck Dossey expounds the importance of soliciting user data to improve patient experiences and the ways in which AI can be utilised within this process.   Companies should start by thinking of ways to leverage unified data sets and digital access points to create and deliver connected,…

USA Paul Bleicher, CEO at OptumLabs, and one of the speakers at the FT US Pharma & Biotech Summit on May 14, shares insights on the benefits we will see AI bring to pharma companies and patients in the short and long term, as well as use cases for the technology.…